Inflammatory and fibrotic biomarkers in patients with atopic dermatitis treated with cendakimab
Cendakimab decreased levels of key inflammatory and fibrotic biomarkers over 16 weeks of treatment in patients with moderate-to-severe AD.
Authors
- Conceição Maria de Oliveira (ORCID: https://orcid.org/0000-0002-2220-5782)
- Evan S. Dellon (ORCID: https://orcid.org/0000-0003-1167-1101)
- Misti Linaberry
- Coryandar Gilvary (ORCID: https://orcid.org/0000-0001-7403-5132)
- Christina M. Charriez
- Jie Li (ORCID: https://orcid.org/0000-0003-2663-731X)
- Sarah Harris (ORCID: https://orcid.org/0000-0002-1265-4453)
- Jonathan I. Silverberg
- Lu Gao (ORCID: https://orcid.org/0009-0001-3355-7265)
Institutions
- University of North Carolina at Chapel Hill (US)
- George Washington University (US)
- Bristol-Myers Squibb (United States) (US)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.jacig.2025.100609
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00